Scott & White Healthcare – Round Rock is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease’s recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).
The MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell LunG Cancer Immunotherapy) study is expected to be one of the largest Phase III trials ever conducted for NSCLC. Scott & White Healthcare – Round Rock is joining with 400 centers in more than 33 countries worldwide in this clinical research effort.
“The randomized, double-blind, placebo-controlled trial will enroll patients that demonstrate the MAGE-A3 biomarker and those who are assessed as stage IB, II, or IIIA resectable Non-Small Cell Lung Cancer,” said Laura Beaty, M.D., principal investigator and hematology/oncologist at Scott & White Healthcare – Round Rock. “The ASCI administration will be started in patients after surgery and standard chemotherapy, and in patients who only receive surgery as a standard of care as the primary endpoint of the trial is disease-free survival,” she said.
Read the full press release here.